HAE on NYSE

Haemonetics

Logo: MelanieCommunications, Public domain, via Wikimedia Commons4

Healthcare company

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$1.3BRevenue, fiscal 20265
$97.3MNet income, fiscal 20265
1971Founded1

Compare with Penumbra, NuVasive or MERIT MEDICAL SYSTEMS INC, or pick any stock.

  • TickerHAE on NYSE1
  • Industrybiomedical engineering1
  • HeadquartersBoston1
  • Websitewww.haemonetics.com
  • Incorporated inMA6
  • Business address125 Summer Street, Boston, Ma 021106
  • Filer categoryLarge accelerated filer6

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

59.0%Gross margin5
11.7%Operating margin5
7.3%Net margin5
-2.0%Revenue growth, 20265
12.2%Return on equity5
1.53×Debt to equity5
$260.4MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Hospital Products and Services brought in 73% of the revenue Haemonetics broke down this way in fiscal 2026.

  1. Hospital Products and Services$588.3M573%up 4% from 2025
  2. Blood Center Products and Services$221.3M527%down 15% from 2025
Products and services by year
Products and services202420252026
Hospital Products and Services$456.3M$564.3M$588.3M
Blood Center Products and Services$283.2M$261.1M$221.3M

Business segments

Hospital brought in 44% of the revenue Haemonetics broke down this way in fiscal 2026.

  1. Hospital$588.3M544%up 4% from 2025
  2. Plasma$524.5M539%down 2% from 2025
  3. Blood Center$221.3M517%down 15% from 2025
Business segments by year
Business segments202420252026
Hospital$456.3M$564.3M$588.3M
Plasma$569.5M$535.4M$524.5M
Blood Center$283.2M$261.1M$221.3M

Regions

United States brought in 74% of the revenue Haemonetics broke down this way in fiscal 2026.

  1. United States$982.2M574%down 3% from 2025
  2. Europe$185.0M514%up 5% from 2025
  3. Asia$87.2M57%down 6% from 2025
  4. Japan$68.2M55%up 9% from 2025
  5. Other Country or Region$11.4M51%down 42% from 2025
Regions by year
Regions202420252026
United States$970.0M$1.0B$982.2M
Europe$160.1M$175.7M$185.0M
Asia$107.5M$92.3M$87.2M
Japan$58.1M$62.4M$68.2M
Other Country or Region$13.3M$19.5M$11.4M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue41¢$546.4M
  • Research and development4¢$59.8M
  • Selling, general and admin33¢$442.4M
  • Other costs12¢$157.4M
  • Income tax2¢$30.7M
  • Profit7¢$97.3M

Out of $1.3B in revenue.5

Where each dollar of operating cash went, fiscal 2026

  • Capital spending11¢$32.8M
  • Share buybacks60¢$175.0M
  • Kept or used elsewhere29¢$85.4M

Out of $293.2M of cash from operations.5

Financial statements

Revenue891011125$1.3B in 2026+38% since 2019
0$500.0M$1.0B$1.5B2019: $967.6M$967.6M20192020: $988.5M$988.5M2020+2%2021: $870.5M$870.5M2021−12%2022: $993.2M$993.2M2022+14%2023: $1.2B$1.2B2023+18%2024: $1.3B$1.3B2024+12%2025: $1.4B$1.4B2025+4%2026: $1.3B$1.3B2026−2%
Gross profit891011125$787.6M in 2026+89% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $417.5M$417.5M20192020: $484.5M$484.5M2020+16%2021: $397.8M$397.8M2021−18%2022: $505.5M$505.5M2022+27%2023: $615.1M$615.1M2023+22%2024: $691.5M$691.5M2024+12%2025: $749.0M$749.0M2025+8%2026: $787.6M$787.6M2026+5%
Operating income891011125$156.7M in 2026+88% since 2019
0$100.0M$200.0M$300.0M2019: $83.5M$83.5M20192020: $103.4M$103.4M2020+24%2021: $89.7M$89.7M2021−13%2022: $80.8M$80.8M2022−10%2023: $156.0M$156.0M2023+93%2024: $164.9M$164.9M2024+6%2025: $221.8M$221.8M2025+35%2026: $156.7M$156.7M2026−29%
Net income891011125$97.3M in 2026+77% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $55.0M$55.0M20192020: $76.5M$76.5M2020+39%2021: $79.5M$79.5M2021+4%2022: $43.4M$43.4M2022−45%2023: $115.4M$115.4M2023+166%2024: $117.6M$117.6M2024+2%2025: $167.7M$167.7M2025+43%2026: $97.3M$97.3M2026−42%

Every line of the income statement in the latest annual report, as filed.5

Period ending2026-03-312025-03-312024-03-31
Net revenues$1.3B$1.4B$1.3B
Cost of goods sold$546.4M$611.9M$617.5M
Gross profit$787.6M$749.0M$691.5M
Research and development$59.8M$62.7M$54.4M
Selling, general and administrative$442.4M$436.8M$429.8M
Amortization of acquired intangible assets$44.0M$48.3M$32.0M
Remeasurement of contingent consideration-$1.9M-$23.0M$0
Impairment of intangible assets$86.5M$2.4M$10.4M
Total operating expenses$630.9M$527.1M$526.7M
Operating income$156.7M$221.8M$164.9M
Interest and other expense, net-$28.7M-$9.7M-$13.0M
Income before provision for income taxes$128.0M$212.1M$151.9M
Provision for income taxes$30.7M$44.4M$34.3M
Net income$97.3M$167.7M$117.6M
Basic (in dollars per share)$2.06$3.33$2.32
Diluted (in dollars per share)$2.05$3.31$2.29
Basic (in shares)47.2M shares50.3M shares50.7M shares
Diluted (in shares)47.4M shares50.7M shares51.4M shares

Compare Haemonetics with another company

The story

The company was founded in 1971. Haemonetics started out producing the containers and bags required for blood collection. The Latham Bowl was a disposable container that could automate the separation of blood by centrifugation. Through the 90's, the company added additional product lines and technologies. The company opened a manufacturing facility in Holbrook, Massachusetts in 1988.

In 1995 the company purchased the Intravenous Solutions manufacturing facility in Union, South Carolina.

Additional acquisitions grew the company and expanded its services. In the following years the company branched off to making the whole plasma collection station including the machine, supplies and software for plasma collection. These acquisitions included Edmonton-based Fifth Dimension (5D) Information Systems to gain entry into the blood and plasma software industry. Further acquisitions include Chicago-based Arryx in July 2006, Information Data Management, Inc. in January 2007, the acquisition of a division of Haemoscope in 2007, the acquisition of Infonale in July 2007, and, in 2009, Chico, California-based Altivation and Tucson, Arizona-based Sebra.

On August 21, 2007, 5D and IDM were officially merged into a new subsidiary called Haemonetics Software Solutions. The employees at both Edmonton (5D) and Rosemont (IDM) continue to work from their respective offices.

Further acquisitions included the April 2009 acquisition of Neoteric Technology Ltd and the April 2010 acquisition of California-based Global Med Technologies, Inc. Haemonetics acquired the Pall Corporation's transfusion medicine business on August 1, 2012 for ~$550 million.

In April 2024, it was announced Haemonetics had completed its acquisition of the Chicago-headquartered medical device temperature regulation manufacturer, Attune Medical for $160 million.

From Wikipedia’s article on Haemonetics, shared under CC BY-SA 4.0.7

Leadership

Who has led Haemonetics, and when. Pick a name to see everywhere that person has worked.

Products and brands

Haemonetics products can be considered as belonging to two broad categories. Donor products (marketed to the blood donation industry, these include products that automate the blood donation process, automate the processing of blood, support pathogen inactivation and bacterial detection of blood, and test blood hematocrit); and products that are marketed to the surgical suite for blood loss management for patients. These products include surgical blood salvage (or "autotransfusion") devices, surgical field blood suction systems, and blood and patient warming systems.

Hemostasis

TEG 5000

Kaolin TEG

Kaolin TEG with Heparinase

Read the full text

RapidTEG

TEG Functional Fibrinogen

TEG PlateletMapping

TEG 6S

From Wikipedia’s article on Haemonetics, shared under CC BY-SA 4.0.7

Timeline

  1. Jan 3, 1994Went public Listed on NYSE1
  2. 1971Founded Founded1

Recent filings

  1. Oct 8, 20268-K
  2. Aug 18, 20268-K
  3. Aug 12, 2026SCHEDULE 13G/A
  4. Aug 6, 20268-K
  5. Aug 6, 202610-Q
  6. Aug 6, 2026S-8
  7. Jul 28, 20268-K
  8. Jul 28, 20263 PRIMARY DOCUMENT
  9. Jul 28, 20264 PRIMARY DOCUMENT
  10. Jul 28, 20264 PRIMARY DOCUMENT
  11. Jul 28, 20264 PRIMARY DOCUMENT
  12. Jul 28, 20264 PRIMARY DOCUMENT
  13. Jul 28, 20264 PRIMARY DOCUMENT
  14. Jul 28, 20264 PRIMARY DOCUMENT
  15. Jul 28, 20264 PRIMARY DOCUMENT

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2